June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Sustained dorzolamide release prevents axonal and retinal ganglion cell loss in a rat model of IOP-glaucoma
Author Affiliations & Notes
  • Ian Pitha
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
    Ophthalmology, Center for Nanomedicine, Johns Hopkins University, Baltimore, Maryland, United States
  • Elizabeth Cone-Kimball
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Ericka Oglesby
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Mary Ellen Pease
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Jie Fu
    Ophthalmology, Center for Nanomedicine, Johns Hopkins University, Baltimore, Maryland, United States
  • Yoo-Chun Kim
    Ophthalmology, Center for Nanomedicine, Johns Hopkins University, Baltimore, Maryland, United States
  • Julie Schaub
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
  • Qi Hu
    Ophthalmology, Center for Nanomedicine, Johns Hopkins University, Baltimore, Maryland, United States
  • Justin Hanes
    Ophthalmology, Center for Nanomedicine, Johns Hopkins University, Baltimore, Maryland, United States
  • Harry A Quigley
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
    Ophthalmology, Center for Nanomedicine, Johns Hopkins University, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Ian Pitha, None; Elizabeth Cone-Kimball, None; Ericka Oglesby, None; Mary Ellen Pease, None; Jie Fu, None; Yoo-Chun Kim, None; Julie Schaub, None; Qi Hu, None; Justin Hanes, GrayBug (S), Kala (P); Harry Quigley, None
  • Footnotes
    Support  NIH/NEI K08EY024952, KKESH-Wilmer Collaboration
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 853. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ian Pitha, Elizabeth Cone-Kimball, Ericka Oglesby, Mary Ellen Pease, Jie Fu, Yoo-Chun Kim, Julie Schaub, Qi Hu, Justin Hanes, Harry A Quigley; Sustained dorzolamide release prevents axonal and retinal ganglion cell loss in a rat model of IOP-glaucoma. Invest. Ophthalmol. Vis. Sci. 2017;58(8):853.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : IOP-lowering eye drops are a mainstay of glaucoma treatment; however, they require patient adherence, can be difficult to administer, and can cause ocular surface toxicity. Previously, we developed a microparticle formulation of dorzolamide (DPP) that lowers IOP in normotensive rabbits for over 30 days. We hypothesize that IOP lowering provided by a single application of DPP would prevent retinal ganglion cell (RGC) loss in a rat model of glaucoma.

Methods : We injected either DPP or control microparticles intravitreally in Wistar rats. Two days later, unilateral ocular hypertension was induced by translimbal, diode laser treatment by a surgeon masked to treatment group. IOP and clinical exams were performed until sacrifice 6 weeks after laser treatment. RGC loss was measured by masked observers in both optic nerve cross-sections and RGC layer counts from retinal whole mounts.

Results : Cumulative IOP exposure was significantly reduced by DPP injection: 49 + 48 mm Hg days versus 227 ± 191 mm Hg days in control microparticle eyes (p=0.012, t test). While control-injected eyes increased in axial length by 2.4 ± 1.7%, DPP eyes did not significantly enlarge (0.3 ± 2.2%, difference from control, p = 0.03, t test). RGC loss was significantly less in DPP eyes compared to microparticle injection alone (axon count reduction: 21% versus 52%; RGC reduction: 25% versus 50% (beta tubulin labeling); p=0.02, t test).

Conclusions : A single injection of DPP microparticles, reduced IOP elevation and RGC loss in a rat model of glaucoma. The results demonstrate that a single injection of a controlled release IOP-lowering formulation can reduce glaucomatous RGC loss.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×